Weigao Blood Purification's plan to acquire 100% equity in Weigao Purui through share issuance has been approved by the M&A and Restructuring Review Committee of the Shanghai Stock Exchange. Under the proposal, the company intends to purchase the entire equity of Shandong Weigao Purui Pharmaceutical Packaging by issuing shares, with a transaction price of 8.511 billion yuan, an issue price of 31.29 yuan per share, and approximately 272 million shares to be issued, representing 39.43% of the total share capital of the listed company after the issuance. The target company's main business is the research, development, production, and sale of pharmaceutical packaging materials such as pre-filled drug delivery systems and automatic safety drug delivery systems. Upon completion of the transaction, Weigao Blood Purification will add pharmaceutical packaging to its main business and integrate its own hollow fiber filtration technology advantages with the target company's customer resources to jointly explore the upstream biopharmaceutical market.
Shandong Weigao BloodAcquisition approved, expanding into pharmaceutical packaging.
Target company being acquired, likely positive for its shareholders.
